$1250 | Single User
$1800 | Site License
$2500 | Global License

Non Small Cell Lung Cancer Pipeline Drugs: Opportunity Assessments, Epidemiology Forecast, Market Dynamics and Pipeline Analysis H2 2020
[Lowest Price Guaranteed: $1,250]

Published by Gervano R A: 28 Aug 2019 | 270520 | In Stock
Related Topics: Cancer , Drug , Lung Cancer

Introduction

GervanoRA’s Pipeline Drug Analytics Report "Non Small Cell Lung Cancer Pipeline Drugs: Opportunity Assessments, Epidemiology Forecast, Market Dynamics and Pipeline Analysis H2 2020" provides a detailed overview on Non Small Cell Lung Cancer Competitive Space. Report provides deep insights on pipeline analytics outlook, drivers, restraints and unmet needs of Non Small Cell Lung Cancer pipeline drugs, Pipeline Analytics, Epidemiological Studies, Deals Analytics, Patent Analytics of Pipeline Drugs, Pipeline Drug Descriptions and Development Milestones, Clinical Trial Analytics, Competitive Landscape and Opportunity Assessments and Emerging Company Profiles.

Pipeline Analytics Outlook:

Report summarize the comparative snapshots of all pipeline drugs as per the segments like stages of development, Geography, Route of Administration, Drug Class, Mechanism of Action, molecule type, target receptors and company types.

Drivers, Restrains, Unmet Needs and Opportunities:

Report offers and provides a deep knowledge on the drivers, restraints and unmet needs and the opportunities derived upon a far-reaching study on the market trends and underlying factors affecting Non Small Cell Lung Cancer landscape.

Pipeline Analytics:

The section covers all the molecules (drug candidates) in different stages of development (Discovery, Pre-clinical, Phase 1, Phase 2, Phase 3 and Pre-registration). It also offers information about the terminated and discontinued molecules. Analytics have been provided by Geography (covers major regions like the US, EU, Asia); by Route of Administration, by Drug Class and by Mechanism of Action. Report explains pipeline analytics by molecule type, target receptor and pipeline analytics by company type. Report also covers pipeline analytics by Universities and Institutes.

Epidemiological Studies:

Our Senior Analysts for conducting Epidemiological Studies uses expertise and proprietary tools to understand the prevailing factors affecting the Disease population. Based on demographics, prevalent factors, incidence rate trends and many other geographical factors, Senior Analysts predicts the future numbers of the affected population over the forecast period, even suggesting the preventative measures.

Deals Analytics:

The report bestows explicit information about the collaborations and partnering activities and trend in Non Small Cell Lung Cancer landscape, including details about different deals types like Mergers and Acquisitions, Licensing deals, Partnering deals, Collaboration Agreements, Series Financings, Grants and Fundings, etc occurring between 2010-2020.

Patent Analytics of Pipeline Drugs:

The section even contains a thorough analysis on the intellectual property pertaining to Non Small Cell Lung Cancer pipeline drugs. Profound analytics have been provided related to the patent issuance and applications, patent expiries, patent extensions, etc to gain a complete knowledge on the new market entries filling up the gaps due to the patent expiries.

Pipeline Drug Descriptions and Development Milestones:

Report provides detailed pipeline drugs descriptions covering all key aspects of the pipeline drugs like intended indications, mechanism of action, route of administration and role in pathophysiological conditions. Report even covers all development milestones of the pipeline drugs right from the early research and development to current stage of development.

Clinical Trial Analytics:

The report is inclusive of all the updated clinical trials information, providing details related to the completed clinical trials, ongoing clinical trials, planned clinical trials, even including complete analytics based on sponsors (companies, universities and institutes) involved in the development of Non Small Cell Lung Cancer Therapeutics.

Competitive Landscape and Opportunity Assessments:

The report is an absolute package covering all the companies - Established and emerging companies (Clinical-stage companies, pre-clinical stage companies, startups) actively involved in the R&D of new therapeutics for the treatment of Non Small Cell Lung Cancer. Report provided opportunity assessments by performing a competitive and comparative analysis on the top 20 Emerging companies in the competitive space.

Emerging Company Profiles:

Report features company profiles with data concentrated on: Partnering activities and patent analysis of the company, R&D efforts and advancements, Comparison of internal investment and external funding, Achievements of special regulatory allowances and Outline of in-licensing/out licensing opportunities.

Table of Contents
for Non Small Cell Lung Cancer Pipeline Drugs: Opportunity Assessments, Epidemiology Forecast, Market Dynamics and Pipeline Analysis H2 2020

  • CHAPTER 01: INTRODUCTION

    1.1. REPORT DESCRIPTION

    1.2. METHODOLOGY

    1.3. ABOUT US: GERVANORA DATA SERVICES

    CHAPTER 02: EXECUTIVE SUMMARY

    2.1. REPORT SUMMARY

    2.2. KEY EVENTS IN THE NON SMALL CELL LUNG CANCER COMPETITIVE SPACE

    2.3. REPORT MAJOR FINDINGS

    2.3.1. DRIVERS

    2.3.2. RESTRAINTS

    2.3.3. OPPORTUNITIES

    CHAPTER 03: PIPELINE ANALYTICS OUTLOOK

    3.1. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS

    3.1.1. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY STAGE OF DEVELOPMENT

    3.1.2. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY GEOGRAPHY

    3.1.3. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY ROUTE OF ADMINISTRATION

    3.1.4. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY DRUG CLASS

    3.1.5. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY MECHANISM OF ACTION

    3.1.6. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY MOLECULE TYPE

    3.1.7. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY MOLECULAR TARGET

    3.1.8. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY COMPANY TYPE

    3.2. UNMET NEEDS AND MARKET DEMANDS

    3.2.1. UNMET NEEDS AND MARKET DEMANDS FOR NEWER THERAPIES

    3.2.2. UNMET NEEDS AND MARKET DEMANDS BY ROUTE OF ADMINISTRATION

    3.2.3. UNMET NEEDS AND MARKET DEMANDS BY GEOGRAPHY

    3.3 MARKET DYNAMICS OF NON SMALL CELL LUNG CANCER COMPETITIVE LANDSCAPE

    CHAPTER 04: DISEASE OVERVIEW AND EPIDEMIOLOGICAL STUDIES

    4.1. DISEASE DEFINITION AND SYMPTOMS

    4.2. DISEASE CAUSE AND PATHOPHYSIOLOGY

    4.3. DISEASE DIAGNOSIS

    4.4. TREATMENT ALGORITHM AND GUIDELINES

    4.5. EPIDEMIOLOGY STUDIES

    3.5.1. GLOBAL AND HISTORICAL TRENDS

    4.6. EPIDEMIOLOGY FORECAST

    4.6.1. FORECAST METHODOLOGY AND ASSUMPTIONS

    4.6.2. PROBABILISTIC EPIDEMIOLOGY FORECAST

    CHAPTER 05: DEALS (M&A) ANALYTICS OF NON SMALL CELL LUNG CANCER COMPETITIVE LANDSCAPE

    4.1. DEALS (MERGERS/ ACQUISITIONS/ COLLABORATIONS)

    4.1.1 DEALS ANALYTICS BY DEAL TYPE

    4.1.1.1. COLLABORATION DEALS

    4.1.1.2. LICENSING DEALS

    4.1.1.3. FINANCING DEALS

    4.1.2 DEALS ANALYTICS BY ANNUAL FREQUENCY

    4.1.3 DEALS ANALYTICS BY ACTIVE PLAYER

    CHAPTER 06: PATENT ANALYTICS OF NON SMALL CELL LUNG CANCER PIPELINE DRUGS

    6.1. PATENT ANALYTICS BY GEOGRAPY

    6.2. PATENT ANALYTICS BY PATENT EXPIRY

    6.3. PATET ANALYTICS BY SPECIAL ALLOWANCES AND TERM EXTENSIONS

    CHAPTER 07: PIPELINE DRUGS ANALYTICS OF NON SMALL CELL LUNG CANCER

    7.1. PIPELINE DRUGS ANALYTICS BY STAGE OF DEVELOPMENT

    5.1.1. PRE-REGISTRATION PIPELINE DRUGS

    5.1.2. PHASE III PIPELINE DRUGS

    5.1.3. PHASE II PIPELINE DRUGS

    5.1.4. PHASE I/II PIPELINE DRUGS

    5.1.5. PHASE I PIPELINE DRUGS

    5.1.6. PRE-CLINICAL PIPELINE DRUGS

    5.1.7. EARLY R&D PIPELINE DRUGS

    5.1.8. INACTIVE AND DISCONTINOUED PIPELINE DRUGS

    5.2. PIPELINE DRUGS ANALYTICS BY GEOGRAPHY

    5.3. PIPELINE DRUGS ANALYTICS BY ROUTE OF ADMINISTRATION

    5.4. PIPELINE DRUGS ANALYTICS BY DRUG CLASS

    5.5. PIPELINE DRUGS ANALYTICS BY MECHANISM OF ACTION

    5.6. PIPELINE DRUGS ANALYTICS BY MOLECULE TYPE

    5.7. PIPELINE DRUGS ANALYTICS BY TARGET RECEPTORS

    5.8. PIPELINE DRUGS ANALYTICS BY COMPANY TYPE

    CHAPTER 08: PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES

    6.1. PRE-REGISTRATION PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES

    6.2. PHASE III PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES

    6.3. PHASE II PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES

    6.4. PHASE I/II PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES

    6.5. PHASE I PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES

    CHAPTER 09: ESTIMATED APPROVAL TIMELINES OF NON SMALL CELL LUNG CANCER PIPELINE DRUGS

    7.1. METHODOLOGY

    7.2. ESTIMATED APPROVAL TIMELINES US & EX-US

    CHAPTER 10: OPPORTUNITY ASSESSMENTS THROUGH COMPETITIVE BENCH-MARKING

    8.1. EXTERNAL DEPENDENCIES

    8.1.1. BUSINESS R&D - INTERNAL INVESTMENT AND EXTERNAL FUNDING

    8.2. PIPELINE PORTFOLIO

    8.3. EXPECTED MARKET ENTRIES

    8.4. PATENTS AND EXCLUSIVITY

    8.5. MARKET DYNAMICS AND PARTNERING

    8.6. ACHIEVEMENTS OF SPECIAL REGULATORY ALLOWANCES

    8.7. COMPANY DEVELOPMENTS

    CHAPTER 11: CURRENT AND FUTURE COMPETITIVE LANDSCAPE

    9.1. EMERGING COMPANIES

    9.1.1 EMERGING COMPANY PROFILES

List Of Tables
in Non Small Cell Lung Cancer Pipeline Drugs: Opportunity Assessments, Epidemiology Forecast, Market Dynamics and Pipeline Analysis H2 2020

LIST OF TABLES

• TABLE 01: NON SMALL CELL LUNG CANCER REPORT HIGHLIGHTS IN NUMERICALS

• TABLE 02: COLLABORATION DEALS IN NON SMALL CELL LUNG CANCER THERAPEUTIC AREA

• TABLE 03: LICENSING DEALS IN NON SMALL CELL LUNG CANCER THERAPEUTIC AREA

• TABLE 04: FINANCING DEALS IN NON SMALL CELL LUNG CANCER THERAPEUTIC AREA

• TABLE 5: NON SMALL CELL LUNG CANCER PHASE III PIPELINE MOLECULES

• TABLE 6: NON SMALL CELL LUNG CANCER PHASE II PIPELINE MOLECULES

• TABLE 7: NON SMALL CELL LUNG CANCER PHASE I/II PIPELINE MOLECULES

• TABLE 8: NON SMALL CELL LUNG CANCER PHASE I PIPELINE MOLECULES

• TABLE 9: PRECLINICAL STAGE DRUG CANDIDATES FOR NON SMALL CELL LUNG CANCER

• TABLE 10: LIST OF PIPELINE MOLECULES OF PARENTERAL ROUTE OF ADMINISTRATION

• TABLE 11: LIST OF PIPELINE MOLECULES OF ORAL ROUTE OF ADMINISTRATION

• (Remaining Tables can be seen in detailed Report)

List Of Figures, Charts and Diagrams
in Non Small Cell Lung Cancer Pipeline Drugs: Opportunity Assessments, Epidemiology Forecast, Market Dynamics and Pipeline Analysis H2 2020

LIST OF FIGURES

• FIGURE 01: KEY EVENTS IN THE NON SMALL CELL LUNG CANCER COMPETITIVE SPACE

• FIGURE 02: NON SMALL CELL LUNG CANCER DEAL ANALYTICS BY DEAL TYPE

• FIGURE 03: NON SMALL CELL LUNG CANCER DEAL ANALYTICS BY DEAL FREQUENCY

• FIGURE 04: PIPELINE MOLECULES - CLINICAL VS PRECLINICAL & EARLY R&D

• FIGURE 05: TOTAL PIPELINE MOLECULES VS STAGE OF DEVELOPMENT

• FIGURE 06: NON SMALL CELL LUNG CANCER DRUGS PIPELINE ANALYTICS BY ROA

• FIGURE 07: NON SMALL CELL LUNG CANCER DRUGS PIPELINE ANALYTICS BY PARENTERAL ROA

• FIGURE 08: PARENTERAL DRUGS PIPELINE ANALYTICS BY HSD

• FIGURE 09: ORAL DRUGS PIPELINE ANALYTICS BY STAGE OF DEVELOPMENT

• FIGURE 10: TOTAL PIPELINE MOLECULES V/S DRUG CLASSES

• FIGURE 11: PIPELINE DRUG CLASS ANALYTICS BY STAGE OF DEVELOPMENT

• FIGURE 12: NON SMALL CELL LUNG CANCER PIPELINE DRUGS BIOLOGICALS VS SMALL MOLECULES

• FIGURE 13: NON SMALL CELL LUNG CANCER PIPELINE DRUGS ANALYTICS BY MOLECULE TYPE VS STAGE OF DEVELOPMENT

• FIGURE 14: NON SMALL CELL LUNG CANCER COMPANIES (NUMBER, PERCENT SHARE)

• FIGURE 15: GEOGRAPHICAL CATEGORIZATION OF COMPANIES WORKING ON NON SMALL CELL LUNG CANCER

• (Remaining Figures can be seen in detailed Report)

Additional Details

Publisher

Gervano R A

Publisher Information

GervanoRA Data Services LLP is a premier provider of syndicated research reports, custom research reports, and consulting services, based in Goa. It provides Market Research And Analysis Services to its clients globally.



GDS aims to deliver a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, aerial views of the competitive framework, and future market trends.



At GervanoRA Data Services, we’re playing our part to help clients stay ahead of the curve. We collaboratively work with a wide range of organizations to garner valuable key insights.

Reference

270520 | GERPH526

Number of Pages

129

Report Format

PDF

Gervano R A Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Global Non-Small Cell Lung Cancer Partnering 2010 to 2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Oct 2016 by Current Partnering USD $1,495 More Info
Medical Affairs Reputations Non-small Cell Lung Cancer US
IntroductionTop medical affairs team safely ahead, but competition for 2nd and 3rd place is fierceIn...
01 Mar 2016 by FirstWord Pharma USD $5,995 More Info
Medical Affairs Reputations Non-small Cell Lung Cancer EU5
IntroductionFour medical affairs teams battling it out for top spot. How does your team compare?In t...
01 Mar 2016 by FirstWord Pharma USD $5,995 More Info
Non-Small Cell Lung Cancer: Update Bulletin [Jan 2016]
IntroductionGain new KOL insights on the latest events that have the potential to shape the targeted...
01 Jan 2016 by FirstWord Pharma USD $995 More Info
Small Bone Innovations, Inc. - Medical Equipment - Deals and Alliances Profile
SummarySmall Bone Innovations, Inc. (SBI) is medical equipment company that develops and distributes...
23 Oct 2015 by Global Data USD $250 More Info
Non-Small Cell Lung Cancer: KOL Insight
IntroductionNon-Small Cell Lung Cancer: KOL Insight offers detailed expert opinion on the continuing...
01 Jul 2015 by FirstWord Pharma USD $7,900 More Info
Physician Views – Taking a post-ASCO pulse on the PD-L1 biomarker debate in non-small-cell lung cancer
ScopeThe data presented at this year's ASCO annual meeting, which has subsequently fuelled the most ...
01 Jun 2015 by FirstWord Pharma USD $695 More Info
Physician Views: Oncologist expectations for immunotherapy in first-line non-small-cell lung cancer
ScopeMuch of the debate around cancer immunotherapy at the recent ASCO annual meeting focused on the...
01 Jun 2015 by FirstWord Pharma USD $695 More Info
Physician Views: Will an Opdivo/Yervoy combination succeed in melanoma and can Keytruda keep pace in non-small-cell lung cancer?
Scope New data presented at the annual meeting of the American Association for Cancer Research (AACR...
23 Apr 2015 by FirstWord Pharma USD $695 More Info
Physician Views: Reaction to Bristol-Myers Squibb's Opdivo data in non-small-cell lung cancer
Scope Studies of Bristol-Myers Squibb's PD-1 inhibitor nivolumab in non-small-cell lung cancer (NSCL...
06 Nov 2014 by FirstWord Pharma USD $695 More Info

This report is published by Gervano R A

GervanoRA Data Services LLP is a premier provider of syndicated research reports, custom research reports, and consulting services, based in Goa. It provides Market Research And Analysis Services to its clients globally.

GDS aims to deliver a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, aerial views of the competitive framework, and future market trends.

At GervanoRA Data Services, we’re playing our part to help clients stay ahead of the curve. We collaboratively work with a wide range of organizations to garner valuable key insights.

Download Free Report Summary PDF

Non Small Cell Lung Cancer Pipeline Drugs: Opportunity Assessments, Epidemiology Forecast, Market Dynamics and Pipeline Analysis H2 2020 | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...